— Know what they know.
Not Investment Advice

NAGE NASDAQ

Niagen Bioscience Inc
1W: -2.4% 1M: -20.0% 3M: -25.8% YTD: -61.0% 1Y: -67.1% 3Y: +89.2% 5Y: -58.4%
$2.50
+0.06 (+2.46%)
 
Weekly Expected Move ±6.0%
$2 $2 $2 $3 $3
NASDAQ · Healthcare · Biotechnology · Tech Score Strong Sell · Power 31 · $193.1M mcap · 52M float · 1.17% daily turnover · Short 44% of daily vol
Credit Risk of going bust: lower than 83% of companies Debt: 1.2% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.00 (down 99.9%), Niagen Bioscience Inc would be worth roughly what it owes.
Total debt $2.3M against a stock market value of $193.1M.
Distance to default 10.65 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $1.2M (short-term plus half of long-term), stock volatility 47.6%; Altman Z'' 4.93. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Smart Money Score
Watch 25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$193.1M
52W Range2.385-7.95
Volume405,770
Avg Volume606,024
Beta2.02
Dividend—
Analyst Ratings
5 Buy 0 Hold 0 Sell
Consensus Buy
Company Info
CEORobert N. Fried
Employees117
SectorHealthcare
IndustryBiotechnology
IPO Date2015-06-24
10900 Wilshire Blvd, Suite 600
Los Angeles, CA 90024
US
310 388 6706
About Niagen Bioscience Inc

Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through Consumer products; Ingredients; and Pharmaceutical Segments. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that regulates cellular metabolism; and develops and commercializes proprietary-based ingredient technologies, including food-grade, Niagen, and pharmaceutical-grade Niagen and supplies these ingredients as raw materials to the manufacturers of consumer products. In addition, it commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient under NIAGEN brand name. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and authorized healthcare practitioners resellers. The company was formerly known as ChromaDex Corporation and changed its name to Niagen Bioscience, Inc. in March 2025. Niagen Bioscience, Inc. was founded in 1999 and is headquartered in Los Angeles, California.

Recent Insider Trades

NameTypeSharesPriceDate
Lopez Carlos Luis A-Award 2,314 $2.71 2026-06-30
Pamir Ozan A-Award 4,255 $2.71 2026-06-30
Fried Robert N A-Award 1,106 $2.71 2026-06-30
Patrick Kristin A-Award 31,746 $3.45 2026-06-24
Shahbazi Hamed A-Award 31,746 $3.45 2026-06-24

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms